Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) FCF Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed FCF Margin for 2 consecutive years, with 27022.48% as the latest value for Q2 2025.

  • Quarterly FCF Margin changed N/A to 27022.48% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 15.76% through Dec 2025, up 115988.0% year-over-year, with the annual reading at 0.49% for FY2025, N/A changed from the prior year.
  • FCF Margin for Q2 2025 was 27022.48% at Neuphoria Therapeutics, up from 76.36% in the prior quarter.
  • The five-year high for FCF Margin was 27022.48% in Q2 2025, with the low at 506.72% in Q4 2024.